Sunday, 27 September 2015
Novartis targeted therapy snippet
Discussion with Novartis about the Dabrafenib/Trametinib combo - as we suspected you dont really need to keep the Trametinib in the fridge - they will be re-issuing advice to corroborate this shortly ...
Next targeted therapy combo Cobimetinib plus Vemurafenib
Combimetinib plus Vemurafenib versus Vemurafenib alone
Copy number of BRAF not relevant for response
13% patients had additional mutations at the beginning BUT it has no effect on response.
and no surprise- combo works better than mono therapy!
T-Vec plus Pembro phase 1b
Update on Phase 1b study
We've been waiting for this one .
T-Vec alone wasn't convincing in the past but this is the combination with Pembro.
Treatment naive patients, 20% Braf pos
Flat dose 200 mg Pembro Q2W used
Side effects typical for immune therapy
Well-tolerated
Unfortunately NO COMMENT on response rates!!!!
Next step: will be tested in a Phase 3 trial
Sunday Melanoma Session at ECC2015- Nivo then Ipi versus Ipi then Nivo in Stage 4 Melanoma
Update on CHECKMATE 064- Hodi
Phase 2 , Nivo post Ipi vs Ipi post Nivo in Melanoma
140 patients
Ipi 3 mg
Nivo 3 mg
1 prior therapy allowed but no Immuno.
Disease progression more in Ipi first
More side effects on Nivo first
Immune- related side effects
Similar to direct combo
50 vs 31% Hepatitis Nivo/ Ipi vs Ipi/ Nivo
ORR 41 vs 20 % confirmed ORR
TUMOUR BURDEN REDUCES FASTER on Nivo first
So- conclusion : Nivo then Ipi higher response rate than Ipi then Nivo but more side effects, similar to what one sees when Ipi and Nivo are giving at the same time.
Caroline Robert commented- surprising as currently one thought that Ipi recruits T-cells that are then activated by PD1.
Also good as it could allow to start with PD1 and only add Ipi when needed, avoiding to limit side effects
Ipi plus Nivo better Nivo/Ipi better than Ipi/ Nivo
To be tested
Intra-tumoral injection of Ipi plus Pd1
Saturday, 26 September 2015
Is innovation affordable?
Efforts are put in finding new ways of making affordable drugs. Innovations comes with effective and safe technologies but cost is making them prohibitive in many parts of the world. During afternoon session an appeal was lunched to get affordable care for everyone who need it.
When resources are highly constraint data collection, early detection, access surgery, x-ray imagining, radiotherapy and access to the basic anti-cancer drugs are seen as priorities. Increasing the means of education and training for the healthcare professionals would make easier the access to the sophisticates techniques and equipments.
On the other hand, to assure at least the access to the essential drugs is a good solution for other cancers, but not helping when comes about melanoma, where chemotherapy is ineffective. A very good approach to have access to the innovation seems to be running smarter and cheaper clinical trials which would lower the price and make the medicines available earlier for the patients with advanced melanoma and... of course more likely to pass the HTA and to be reimbursed.
Friday, 25 September 2015
Vital Options Advocacy in Action
Interesting discussion from WHO Essential Medicines list, to Global Access issues and what Advocacy organisations need to be doing -
most of all Collaborate between disease areas to be all to put pressure on HTA and Reimbursement Authorities
Come up with plans of action to find strategies to put pressure on Regulators and Pharma to talk/negotiate
Get credible data from patients to force access issues to be taken seriously
Who decides what is an essential medicine and patient advocates need to be deeply involved in this area.
If we think access issues are bad in Europe wait until you see the access issues in sub-saharan Africa and India
Collaboration and Transparency.
most of all Collaborate between disease areas to be all to put pressure on HTA and Reimbursement Authorities
Come up with plans of action to find strategies to put pressure on Regulators and Pharma to talk/negotiate
Get credible data from patients to force access issues to be taken seriously
Who decides what is an essential medicine and patient advocates need to be deeply involved in this area.
If we think access issues are bad in Europe wait until you see the access issues in sub-saharan Africa and India
Collaboration and Transparency.
Thursday, 24 September 2015
ONE more sleep!
The European Cancer Congress in Vienna will start tomorrow!
We will be blogging about interesting findings here. You will also find us on twitter- if you subscribe to https://twitter.com/MPNEurope/lists/mpneatecc2015 - you will capture all our tweets- and we will obviously post on the MPNE facebook forum.
Safe travel for everyone who's joining us in person, looking forward to seeing you in REAL!
Bettina
Subscribe to:
Posts (Atom)